← Browse by Condition
Medical Condition
glioma
Total Trials
26
Recruiting Now
26
Trial Phases
Phase 2, Phase 3, Phase 2, Phase 3
NCT05770544 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT02800486 Phase 2
Recruiting
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Enrollment
37 pts
Location
United States
Sponsor
Northwell Health
NCT04699773
Recruiting
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
Enrollment
32 pts
Location
United States
Sponsor
University of Maryland, Baltim...
NCT06234319
Recruiting
CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma
Enrollment
60 pts
Location
China
Sponsor
Xiao Chen
NCT06818331 Phase 2
Recruiting
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Enrollment
20 pts
Location
China
Sponsor
The Third Affiliated hospital ...
NCT06801730 Phase 2
Recruiting
Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma
Enrollment
38 pts
Location
China
Sponsor
Zhifeng Tian,MD
NCT05580562 Phase 3
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Enrollment
450 pts
Location
United States, Argen...
Sponsor
Jazz Pharmaceuticals
NCT05607407 Phase 2
Recruiting
Methimazole in Patients With Progressive Glioblastoma
Enrollment
19 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
NCT07338539 Phase 2
Recruiting
BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM
Enrollment
108 pts
Location
India
Sponsor
Tata Memorial Centre
NCT03684109
Recruiting
Non-invasive Glioma Characterization Through Molecular Imaging
Enrollment
30 pts
Location
United States
Sponsor
University of Miami
NCT06988475 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT06180434
Recruiting
Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas
Enrollment
320 pts
Location
Netherlands
Sponsor
Erasmus Medical Center
NCT05773326 EARLY_Phase 1
Recruiting
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Enrollment
12 pts
Location
United States
Sponsor
Nader Sanai
NCT01772771
Recruiting
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Enrollment
12,000 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06156150
Recruiting
The Role of B7-H4 in Tumor Vaccine
Enrollment
160 pts
Location
China
Sponsor
Huashan Hospital
NCT05976490
Recruiting
NeuroPathways Intervention for Brain Tumor Patients
Enrollment
50 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT03739411 Phase 1
Recruiting
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Enrollment
140 pts
Location
United States
Sponsor
Susan Chang
NCT06496971 Phase 3
Recruiting
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
Enrollment
32 pts
Location
Taiwan
Sponsor
NaviFUS Corporation
NCT06011109 Phase 1, Phase 2
Recruiting
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Enrollment
30 pts
Location
United States
Sponsor
Aveta Biomics, Inc.
NCT03991832 Phase 2
Recruiting
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Enrollment
58 pts
Location
Canada
Sponsor
University Health Network, Tor...
NCT07263711
Recruiting
Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction
Enrollment
2,000 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
NCT05768178 Phase 2, Phase 3
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
NCT03728673 Phase 2
Recruiting
A Study Utilizing Escitalopram in Glioma Patients
Enrollment
20 pts
Location
United States
Sponsor
University of Nebraska
NCT06412952 EARLY_Phase 1
Recruiting
68Ga-NOTA-RM26 PET/CT in Glioma Patients
Enrollment
30 pts
Location
China
Sponsor
Peking Union Medical College H...
NCT04943913 EARLY_Phase 1
Recruiting
Study of GC101 TIL in Brain Glioma (Soochow2)
Enrollment
50 pts
Location
China
Sponsor
Shanghai Juncell Therapeutics
NCT06116903
Recruiting
Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
Enrollment
60 pts
Location
France
Sponsor
University Hospital, Limoges